September 15th, 2025 – Zug, Switzerland: RGCC International is proud to announce the successful conclusion of the RGCC International Gathering 2025, held from 12–14 September 2025 in Zurich.

Bringing together more than 130 attendees from across the globe, the RGCC International Gathering reaffirmed its position as Europe’s largest and most dynamic meeting of RGCC scientists, clinicians, and collaborators. Over the course of three impactful days, participants explored cutting-edge advancements in cancer diagnostics and autologous treatments, shared clinical insights, and strengthened global collaboration in the fight against cancer.

The event opened with a keynote by Dr. Ioannis Papasotiriou, Founder and Director of RGCC International, who presented RGCC’s most significant research achievements and innovations from the past two years.

The program featured expert-led sessions from RGCC scientists and collaborators, covering a range of pioneering topics such as:

  • Extracellular Vesicles Cancer Theranostics
  • Biomimetic 3D in Vitro Cellular Models to Explore New Cancer Targets
  • The Role of Quality in Food Supplements
  • Modern Drug Discovery for New and Selective Cancer Therapy

The Gathering also highlighted practitioner experiences with RGCC technologies, including:

  • Functional Application of Liquid Biopsy in Personalizing Cancer Treatment presented by Dr. Conrado Lola (Philippines)
  • Clinician’s Practical Guide to Utilizing RGCC Cancer Testing, presented by Dr. Clayton Bell. (USA)

These were among several insightful practitioner-led presentations, offering real-world perspectives on the application of RGCC technologies in clinical practice.

Beyond presentations, the event fostered collaboration through interactive panels and networking opportunities. The Gathering concluded with an open Q&A session led by Dr. Papasotiriou, providing attendees the opportunity to exchange feedback and engage directly with RGCC leadership.

“The RGCC Gathering is more than a conference. It is a global community working together to advance the future of personalized cancer care,” said Dr. Papasotiriou. “The insights, research, and collaborations forged here will play a vital role in shaping the next chapter of precision oncology.”

About RGCC International:

RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine. Today, RGCC is a leading innovator in the field of oncology diagnostics. Using world-leading technology, equipment, and innovative techniques, our team of scientists has developed a range of liquid biopsies that help physicians track cancer progression and tailor treatment plans based on individual patient profiles.
For more info visit: rgcc-international.com